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Abstract
Background: Alzheimer’s disease (AD) is an inexorable neurodegenerative disease that commonly occurs in the
elderly. The cognitive impairment caused by AD is associated with abnormal accumulation of amyloid-β (Aβ) and
hyperphosphorylated tau, which are accompanied by inflammation. Neural stem cells (NSCs) are self-renewing,
multipotential cells that differentiate into distinct neural cells. When transplanted into a diseased brain, NSCs repair
and replace injured tissues after migration toward and engraftment within lesions. We investigated the therapeutic
effects in an AD mouse model of human NSCs (hNSCs) that derived from an aborted human fetal telencephalon at
13 weeks of gestation. Cells were transplanted into the cerebral lateral ventricles of neuron-specific enolase
promoter-controlled APPsw-expressing (NSE/APPsw) transgenic mice at 13 months of age.
Results: Implanted cells extensively migrated and engrafted, and some differentiated into neuronal and glial cells,
although most hNSCs remained immature. The hNSC transplantation improved spatial memory in these mice,
which also showed decreased tau phosphorylation and Aβ42 levels and attenuated microgliosis and astrogliosis.
The hNSC transplantation reduced tau phosphorylation via Trk-dependent Akt/GSK3β signaling, down-regulated
Aβ production through an Akt/GSK3β signaling-mediated decrease in BACE1, and decreased expression of
inflammatory mediators through deactivation of microglia that was mediated by cell-to-cell contact, secretion of
anti-inflammatory factors generated from hNSCs, or both. The hNSC transplantation also facilitated synaptic
plasticity and anti-apoptotic function via trophic supplies. Furthermore, the safety and feasibility of hNSC
transplantation are supported.
Conclusions: These findings demonstrate the hNSC transplantation modulates diverse AD pathologies and rescue
impaired memory via multiple mechanisms in an AD model. Thus, our data provide tangible preclinical evidence
that human NSC transplantation could be a safe and versatile approach for treating AD patients.
Keywords: Alzheimer’s disease, Human neural stem cells, Transplantation, Trophic factors, Glycogen synthase kinase
3β (GSK3β), Anti-inflammation
Background
Alzheimer’s disease (AD), which is characterized by mem-
ory loss, progressive cognitive decline, and neuropsychi-
atric impairment [1], is a devastating neurological disorder
that occurs predominantly after 65 years of age. The path-
ology observed in the AD brain includes aberrant accu-
mulation of amyloid-β (Aβ) and hyperphosphorylated tau,
which disturb synaptic function, neuronal homeostasis,
and axonal stability, resulting in neuronal loss [1, 2].
Moreover, chronically activated microglia and reactive as-
trocytes in the brain stimulate deleterious effects through
the release of pro-inflammatory cytokines and nitric
oxide/reactive oxygen species [2, 3]. To date, the diverse
drugs used clinically to treat AD provide temporary symp-
tomatic relief, but do not fundamentally alter the progress
of the disease [4]. Therefore, although Aβ-targeted therap-
ies, tau-associated therapies, and anti-inflammatory drugs
have been developed to focus on the molecular pathogen-
esis underlying AD [5–7], an effective treatment has not
been established.
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Neural stem cells (NSCs) from distinct spatiotemporal
neural tissues of mammalian species have the capacity
for self-renewal and can give rise to neurons, astrocytes,
and oligodendrocytes [8–10]. Human NSCs (hNSCs)
isolated from fetal CNS tissue, typically at approximately
6–22 weeks of gestation, are grown as neurospheres in
the presence of epidermal growth factor, fibroblast
growth factor-2 (FGF-2), or both [11–14]. The hNSCs
transplanted into a diseased or injured CNS not only
robustly migrate toward and engraft within areas of
discrete abnormalities, but also replace dysfunctional
tissue and promote survival of injured cells and endogen-
ous tissue repair [15–20]. Therefore, hNSC-based therapy
may provide a substantial benefit by preventing, obstruct-
ing, or reversing AD. Recently, several studies showed that
NSC grafting into the hippocampus improved the cogni-
tive deficits by the recovery of synaptic plasticity and at-
tenuating the expression of proinflammatory cytokines in
AD models [21–25]. However, it is still not clear how
NSC transplantation regulates molecular signaling path-
ways related to AD-like neuropathologies.
In this study, we explored the therapeutic potential of
human fetal brain-derived NSCs in NSE/APPsw trans-
genic mice harboring APP Swedish mutant under the
control of the rat neuron-specific enolase (NSE) pro-
moter. The transgenic mice exhibit increased intracellu-
lar Aβ deposition and tau phosphorylation, and develop
spatial memory deficits at 12 months of age [26]. Herein,
we determined whether hNSC transplantation improved
behavioral deficits in NSE/APPsw transgenic mice, and
characterized the distribution, engraftment, and the differ-
entiation patterns of cells implanted in mouse recipients.
We further investigated whether hNSC transplantation
could modulate Aβ and tau pathology, neuroinflamma-
tion, and synaptic plasticity.
Results
Engraftment, migration, and differentiation of human
NSCs following transplantation
Non-engineered hNSCs, lenti-GFP-transduced hNSCs
(Additional file 1: Figure S1), and 2 μM 5-bromo-2′-
deoxyuridine (BrdU)-labeled hNSCs were prepared to
identify grafted cells in multiple brain locations of NSE/
APPsw transgenic mice at 7 weeks post-transplantation.
The grafted human nuclear matrix (hNuMA)+, human
nuclear antigen (hNuC)+, human nestin (hnestin)+, GFP+,
or BrdU+ cells were widely distributed from the trans-
plantation site to the subventricular zone (SVZ), white
matter tracts, striatum, thalamus, hypothalamus, and cor-
tex, although a large proportion of the grafted cells was
localized to the SVZ (Fig. 1a-j). The majority of hNuMA+
cells expressed hnestin, an immature cell marker (Fig. 1k
and l), whereas others were co-localized with the early
neuronal cell marker neuronal class III β-tubulin (TUJ1)
in the SVZ (Fig. 1m), the oligodendroglial progenitor cell
marker Olig2 in the SVZ and thalamus (Fig. 1n), the
neuroblast marker doublecortin (DCX) in the external cap-
sule (Fig. 1o), the oligodendroglial progenitor cell marker
platelet-derived growth factor receptor-α (PDGFR-α) in
the external capsule (Fig. 1p), and the astrocyte marker
glial fibrillary acidic protein (GFAP) in the cortex (Fig. 1q).
Quantification revealed that most grafted cells expressed
hnestin (82.4 ± 3.3 %), whereas some cells differentiated
into TUJ1+ neurons (5.8 ± 0.9 %), Olig2+ oligodendrocyte
progenitors (2.3 ± 0.4 %), and GFAP+ astrocytes (11.7 ±
2.8 %) (Fig. 1r). These data demonstrated that human fetal
brain-derived NSCs showed extensive migration, robust
engraftment, and differentiation into three CNS neural cell
types, albeit that most cells remained in an immature state
following transplantation. Additionally, some donor-
derived cells still survived in the SVZ, third ventricle, and
thalamus adjacent to the site of transplantation, and differ-
entiated into neuronal or glial cells, albeit that most
remained immature even when analyzed at 3 months fol-
lowing implantation. (Additional file 2: Figure S2). Thus,
implanted hNSCs into the AD model migrate and survive
for a prolonged period, although the number of grafted
cells reduced gradually over time.
Human NSC transplantation improves spatial memory
Mice were grouped into hNSC- (APP-NSC) or vehicle
(Hank’s balanced salt solution–10 mM HEPES [H-H]
buffer only)-injected (APP-Veh) NSE/APPsw transgenic
mice and vehicle-injected wild-type mice (WT-Veh).
The open field test and the accelerating rotarod task
were performed at 5 weeks post-transplantation. No
changes in ambulatory or stereotypic activity were ob-
served in the open field test, which is affected by ex-
ploratory activity and emotionality (Fig. 2a), and
interactions of day or night locomotor activity (Fig. 2b),
respectively, among the groups. In the accelerating
rotarod task, which reflects motor coordination, the
three groups showed no differences in latency to fall
(Fig. 2c). In the Morris water maze test at 6 weeks post-
transplantation, the groups revealed no differences during
the learning phase (Fig. 2d). However, target quadrant oc-
cupancy was significantly lower, and fewer platform cross-
ings were observed in the APP-Veh group (21.63 ± 1.58 s
and 2.68 ± 0.49, respectively) than in the WT-Veh group
(30.04 ± 2.11 s and 4.84 ± 0.67, respectively; p < 0.01;
Fig. 2e). Moreover, the APP-NSC group showed a sig-
nificant increase in these parameters (27.88 ± 1.36 s and
4.43 ± 0.25, respectively) compared with the APP-Veh
group (p < 0.01; Fig. 2e). Additionally, in the water maze
test at 12 weeks post-transplantation, the overall learn-
ing phase was not different among the three groups
(Fig. 2f ). The APP-Veh group showed a significant
decrease in target quadrant occupancy and platform
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crossing compared with the WT-Veh group (21.58 ±
2.70 versus 32.58 ± 1.76 s, p < 0.01, and 2.70 ± 0.34
versus 4.70 ± 0.48, p < 0.05, respectively; Fig. 2g). How-
ever, hNSC grafting tended to increase these values in
transgenic mice, although this increase was not statis-
tically significant (26.70 ± 2.31 s and 3.75 ± 0.58, re-
spectively; Fig. 2g). These results indicated that hNSC
transplantation ameliorated the impaired spatial mem-
ory without causing the mice to exhibit atypical loco-
motion, spontaneous motor alterations, or aberrant
motor coordination but did not prevent long-term
progressive cognitive deficits in transgenic mice.
Human NSC transplantation inhibits tau phosphorylation
We measured the level of phosphorylated tau (AT180)
in hNSC- and vehicle-injected NSE/APPsw transgenic
mice because aberrant phosphorylation of tau worsens
cognitive function via axonal and synaptic disruption in
AD [2, 6]. Vehicle-injected transgenic mice showed
stronger AT180 immunoreactivity than vehicle-injected
Fig. 1 Transplantation of hNSCs into NSE/APPsw transgenic mice. a Schematic drawing of a representative coronal brain section, illustrating the
wide distribution of hNuMA+ grafted cells (red dots). Asterisks indicate the transplantation sites. Lowercase letters represent the site captured in
the respective photomicrographs shown in (b–j). b–e GFP-expressing hNSCs (b and e) or hNuMA+ cells (c and d) are largely engrafted from the
LV or third ventricle (3 V) to the SVZ, and from dorsal 3 V (D3V) to the thalamus and hypothalamus. f Some hnestin+ cells are detected
in the thalamus. g–j The grafted cells migrate along the white matter tracts: BrdU+ cells in the corpus callosum (cc; g); hNuC+ cells in
the cingulum (h); and hNuMA+ cells in the external capsule (i), and toward the cortex (j). k–n Most hNuMA+ cells express hnestin in the cortex (k)
and external capsules (l), whereas a few hNuMA+ cells are co-localized with either TUJ1+ or Olig2+ cells in the SVZ (m) and thalamus (n), respectively.
Arrows in N indicate hNuMA/Olig2 double-labeled cells. o–q A few hNuMA+ cells express DCX (o) or PDGFR-α (p) in the white matter tracts, and GFAP
(q) in the cortex. Arrowheads in Q indicate co-localization of hNuMA and GFAP, representing z-stack confocal images (three small images in the right
panel of q). r Differentiation patterns of grafted hNSCs in transgenic mice (n = 4, where n is the number of mice). In k–m, o, and p, z-stack images are
built and compiled to maximal intensity projections. Scale bars, 50 μm
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wild-type mice (Fig. 3a and b), consistent with pervious
report [26]. Notably, hNSC-transplanted transgenic mice
showed a significant decrease in the intensity of AT180
immunoreactivity in the hippocampal CA1 and cortical
regions compared with their vehicle-injected cohorts
(p < 0.05; Fig. 3b-h). In addition, western blot indicated
that levels of tau phosphorylation were significantly
attenuated by hNSC transplantation in transgenic mouse
brain (AT180 [Thr231], p < 0.05; AT8 [Ser202], p < 0.05;
pTau [Ser404], p < 0.01; PHF13 [Ser396], p < 0.05; Fig. 3i).
Therefore, hNSC transplantation reduced tau phosphor-
ylation in transgenic mouse brain, suggesting that
grafted hNSCs widely modulated tau phosphorylation in
a diffusible fashion because the hNSCs were rarely found
in the hippocampus.
Human NSC transplantation activates Trk-dependent Akt/
GSK3β signaling
In this study, hNSCs expressed trophic factors including
neurotrophins (BDNF, NTF3, NTF4, NGF, VEGF, FGF2,
and GDNF) that induce Trk-dependent Akt activation
[27] and secreted them into the culture media (Additional
file 3: Figure S3). Moreover, hNSC transplantation signifi-
cantly increased the levels of neurotrophins in the brains
of transgenic mice compared with those in their vehicle-
injected cohorts (p < 0.05; Fig. 3j). Furthermore, hNSC
transplantation induced significantly higher phosphor-
ylation levels of TrkA/B and Akt, and markedly ele-
vated the level of GSK3β phosphorylation (p < 0.05,
respectively; Fig. 3k), suggesting that tau phosphoryl-
ation was modulated by augmented neurotrophin-
mediated Trk-dependent Akt/GSK3β signaling in
transgenic mice, because GSK3β is the major kinase
phosphorylating tau and its activity is suppressed by
Akt-mediated phosphorylation at Ser9 [28, 29]. Next,
hNSC- or human foreskin fibroblast-derived condi-
tioned media (CM)-treated PC12 cells were incubated
with soluble Aβ42 because abundant Aβ promotes tau
phosphorylation in the cells [30]. The presence of
hNSC-derived CM in Aβ42-treated cells significantly
hampered tau phosphorylation and markedly induced
phosphorylation of TrkA/B, Akt, and GSK3β com-
pared with those in the presence of fibroblast-derived
CM (p < 0.05, respectively; Fig. 3l and m). Therefore,
these results suggested that hNSCs modulated GSK3β
activity through Trk-induced Akt activation to ultim-
ately decrease tau phosphorylation in transgenic mice.
Human NSC transplantation leads to reduced Aβ42 levels
We compared the area and amount of the Aβ load in
hNSC- and vehicle-injected NSE/APPsw transgenic mice
because Aβ is directly associated with cognitive decline
in AD [1, 2]. Aβ plaque staining showed no statistically
significant differences in the area or number of Aβ pla-
ques, although the area of Aβ plaques was nonsignifi-
cantly lower in cell-injected mice (total Aβ plaques/
mm2, 1.74 ± 0.58 versus 2.14 ± 0.50; Aβ plaque burden,
0.80 ± 0.32 versus 1.19 ± 0.26; Fig. 4a and b). Addition-
ally, we examined intracellular Aβ42 immunoreactivity,
because a marked accumulation of intracellular Aβ in
some AD models elicits synaptic dysfunction and
Fig. 2 Behavioral phenotypes of hNSC- or vehicle-injected NSE/
APPsw transgenic mice and vehicle-injected wild-type mice. a
Ambulatory and stereotypic activity of the three groups in a 30 min
open field test (APP-NSC, n = 24; APP-Veh, n = 20; and WT-Veh, n = 24).
b Ambulatory and stereotypic locomotor activity over 22 h (APP-NSC,
n = 12; APP-Veh, n = 8; and WT-Veh, n = 14). c Latency to fall in the
accelerating rotarod task (APP-NSC, n = 26; APP-Veh, n = 20; and
WT-Veh, n= 23). d and e Results from the water maze test 6 weeks after
hNSC or vehicle injection. The latency to reach the hidden platform
(escape latency) during the learning phase was recorded d. Target
quadrant occupancy and platform crossing during the probe trial were
measured in the three groups (APP-NSC, n= 21; APP-Veh, n= 19; and
WT-Veh, n= 19; e). f and g Results from the water maze test 12 weeks
post-transplantation. Escape latency during the learning phase in the
three groups (f). Target quadrant occupancy and platform crossing
during the probe trial (APP-NSC, n= 12; APP-Veh, n= 10; and WT-Veh,
n= 10; g). The number of mice (n) in each group is indicated. All data
represent mean ± SEM. Error bars indicate ± SEM. *p < 0.05, **p< 0.01
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cognitive deficits before or without the aggressive develop-
ment of Aβ plaques [31–33]. NSE/APPsw transgenic mice
exhibit more intensive intracellular Aβ42 immunoreactiv-
ity compared with wild-type mice (Fig. 4c, d, f, g, i, and j).
The hNSC transplantation significantly decreased Aβ42
immunoreactivity in the cortex (p < 0.05) but not in the
hippocampus compared with that in the vehicle-injected
cohorts (Fig. 4d, e, g, h, and j–l). Moreover, we found that
detergent-soluble Aβ42 was significantly decreased in the
hNSC-transplanted mice compared with that in the
vehicle-injected mice (0.23 ± 0.02 versus 0.34 ± 0.03 pg/
mg, p < 0.05), whereas detergent-soluble Aβ40 and insol-
uble Aβ40/42 were indistinguishable in both groups as
assessed in whole brain extracts of transgenic mice (sol-
uble Aβ40, 2.01 ± 0.21 versus 1.98 ± 0.19 pg/mg; insoluble
Aβ40, 5.23 ± 0.22 versus 4.93 ± 0.16 pg/mg; and insoluble
Aβ42, 1.23 ± 0.12 versus 1.04 ± 0.06 pg/mg; Fig. 4m).
Therefore, hNSC transplantation appeared to play a key
role in the reduced level of intracellular soluble Aβ42, al-
beit only slightly, in transgenic mouse brain.
Human NSCs alter APP processing by modulating BACE1
expression
We investigated whether hNSC transplantation affected
the expression of BACE1, the essential β-secretase for
APP processing, leading to Aβ production. The brain
levels of BACE1 were substantially reduced in hNSC-
injected NSE/APPsw transgenic mice compared with
those in their vehicle-injected cohorts (p < 0.05; Fig. 4n),
consistent with reports indicating that Akt activation
or GSK3β inactivation reduce BACE1 levels [34, 35].
Moreover, hNSC transplantation induced a significant
decrease in the level of APP C-terminal fragment β
(CTF-β) relative to APP C-terminal fragment α (CTF-α)
compared with that following vehicle injections in trans-
genic mouse brains (p < 0.05; Fig. 4o), reflecting the de-
crease in Aβ production. Furthermore, the expression of
membrane metallo endopeptidase (Mme) and insulin
degrading enzyme (Ide), known as main Aβ degrading
enzymes, showed no significant difference between hNSC-
and vehicle-injected transgenic mice (Additional file 4:
Fig. 3 hNSC transplantation reduces tau phosphorylation via Trk-induced Akt/GSK3β signaling in the NSE/APPsw transgenic mouse brain. a–c
Photomicrographs of AT180 immunostaining in the brains of vehicle-injected wild-type (WT-Veh; a), vehicle-injected transgenic (APP-Veh; b), and
hNSC-injected transgenic (APP-NSC; c) mice. d–g AT180 immunoreactivity in the stratum radiatum of the hippocampal CA1 region (HIPP; inside
the dotted rectangle in d and e) and the posterior parietal cortex (CTX; f and g) in hNSC- and vehicle-injected transgenic mice. Or, oriens layer;
Pyr, pyramidal cell layer; Rad, stratum radiatum. h Immunohistochemical image analyses of AT180 immunoreactivity comparing hNSC graft (NSC,
n = 4) and vehicle injection (Veh, n = 4) in the transgenic mice. i Levels of phosphorylated tau (AT180, AT8, pTau, and PHF13) on western blot
image analyses in brains of vehicle-injected (n = 5) and hNSC-injected (n = 6) transgenic mice. j Levels of neurotrophins (BDNF, NTF3, NGF, and
NTF4) on western blot image analyses in brains of vehicle-injected (n = 3) and hNSC-injected (n = 4) transgenic mice. k Levels of phosphorylated
TrkA/B, Akt and GSK3β using western blot analysis on brains of vehicle-injected (n = 3) and hNSC-injected (n = 3) transgenic mice. l and m
Relative levels of phosphorylated tau (l) and kinases related to Trk-dependent Akt/GSK3β signaling (m) using western blot image analyses
from Aβ42-treated PC12 cells in the presence of hNSC-derived CM (NSC, n = 3) and fibroblast-derived CM (Fib, n = 3). Scale bars, 100 μm.
The number of mice (n) in H-K is indicated. The number of experiments (n) in L and M is indicated. All data represent mean ± SEM. Error bars
indicate ± SEM. *p < 0.05, **p < 0.01
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Fig. 4 (See legend on next page.)
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Figure S4A). Additionally, although hNSCs expressed vari-
ous Aβ-degrading enzymes in vitro, there were no differ-
ences in the levels of Aβ42 in the media containing 1 μM
soluble Aβ42 peptides between wells with and without in-
cubation with hNSCs. (Additional file 4: Figure S4B).
Next, APPsw-expressing SK-N-MC human neuroblast-
oma cells were incubated with the hNSC- or fibroblast-
derived CM. Notably, hNSC-derived CM-treated cells
showed substantially lower levels of BACE1 and APP
CTF-β/CTF-α than cells treated with fibroblast-derived
CM (p < 0.05), leading to a decrease of Aβ in the culture
media (p < 0.05) and higher phosphorylation of Akt and
GSK3β (p < 0.05) (Fig. 4p). Taken together, these results
suggested that grafted hNSCs were involved in APP pro-
cessing through Akt/GSK3β signaling-mediated BACE1
modulation in transgenic mouse brain.
Human NSC transplantation decreases astrogliosis and
microgliosis
Because activation of astrocytes and microglia in mutant
APP-expressing mice aggravate neurodegenerative mi-
lieu by pro-inflammatory mediators, resulting in cogni-
tive impairment [36, 37], we performed staining with
GFAP and the microglial markers Iba1, CD11b, and F4/
80 to examine the effects of hNSC transplantation on
neuroinflammation in NSE/APPsw transgenic mice.
Astrogliosis and microgliosis were markedly enhanced in
vehicle-injected transgenic mice compared with that in
vehicle-injected wild-type mice (Fig. 5a, b, d and e),
whereas hNSC transplantation significantly reduced the
level of GFAP and Iba1 immunoreactivity in transgenic
mice (p < 0.05; Fig. 5b, c, e-i, l and m), respectively. Add-
itionally, the numbers of CD11b+ and F4/80+ cells were
decreased in hNSC-injected transgenic mice compared
with those in their vehicle-injected cohorts (Fig. 5j and k).
Furthermore, hNSC transplantation significantly down-
regulated the expression levels of pro-inflammatory media-
tors (Il1b, Il6, Tnfa, and iNOS) in transgenic mice (pIl1b <
0.05, pIl6 < 0.01, pTnfa < 0.01, and piNOS < 0.05; Fig. 6a).
Collectively, these data indicated that hNSC transplantation
had an anti-inflammatory effect against astrogliosis and
microgliosis in transgenic mice.
Human NSCs attenuate microglial activation through cell-
to-cell contact and secretory molecules
To elucidate the immunomodulatory effects of hNSCs
on microglia, we indirectly or directly cultured lipopoly-
saccharide (LPS)-activated BV2 microglial cells with
hNSCs. Firstly, BV2 cells co-cultured in Transwell
showed a significant reduction in the levels of Il1b, Il6,
and Tnfa, but not iNOS, compared with BV2 cells cul-
tured alone (pIl1b < 0.05, pIl6 < 0.05, pTnfa < 0.05, and
piNOS = 0.827; Fig. 6b). Next, BV2 cells separated from
mixed-culture in the presence of LPS (Additional file 5:
Figure S5A) had significantly lower expression of
Il1b, Il6, Tnfa, and iNOS than BV2 cells cultured
alone (p < 0.05; Fig. 6c). Additionally, we found that
co-cultured hNSCs expressed secretory or cell-to-cell
contact anti-inflammatory factors (TGFB1, IL4, IL13,
CX3CL1, CD47, and CD200) in Transwell and
mixed-cultures, respectively (Fig. 6d and e). Lastly,
we directly cultured gene-knockdown BV2 cells
(Additional file 5: Figure S5B) with hNSCs in the
presence of LPS to identify which factors strongly
expressed in hNSCs abrogate expression of pro-
inflammatory mediators in activated BV2 cells. The
BV2 cells with the TGF-β receptor 2 (Tgfbr2)-knock-
down had significantly increased expression of Il1b,
Il6, and Tnfa (p < 0.05), whereas signal regulatory
protein α (Sirpa as the CD47 receptor)-knockdown
BV2 cells exhibited significantly increased expression
of only Il6 (p < 0.05; Fig. 6f ). CD200 receptor 1
(Cd200r1)-knockdown BV2 cells showed significantly
elevated levels of Il1b, Il6, and iNOS (p < 0.05;
Fig. 6f ). These data indicated that hNSCs attenuated
the microglial expression of pro-inflammatory media-
tors, suggesting that TGF-β1, CD47, and CD200 gen-
erated in hNSCs had anti-inflammatory effects on
activated microglia.
(See figure on previous page.)
Fig. 4 hNSC transplantation decreases brain intracellular soluble Aβ42 levels by regulating BACE1 in NSE/APPsw transgenic mice. a Photomicrographs
of Aβ plaque (6E10) staining in hNSC-injected (NSC) and vehicle-injected (Veh) transgenic mice. Scale bar, 1 mm. b The number of Aβ plaques per unit
area (left) and the percent area of the Aβ plaque load (right) between hNSC graft (NSC) and vehicle injection (Veh; n = 3 per group). c–l Representative
images of Aβ42 immunostaining in the brains of vehicle-injected wild-type mice (WT-Veh; c), and of vehicle-injected (APP-Veh; d) and hNSC-injected
(APP-NSC; e) transgenic mice. Aβ42 immunostaining of each group in the pyramidal cell layer of the hippocampal CA1 region (HIPP; f–h) and the
posterior parietal cortex (CTX; i–k). The relative levels of Aβ42 immunostaining in vehicle-injected (Veh) and hNSC-injected (NSC) transgenic mice
(n = 4 per group; l). Scale bar, 100 μm (e and h) and 50 μm (k). m Levels of detergent-soluble (Sol) Aβ40/42 and detergent-insoluble (Insol) Aβ40/42
in the brains of hNSC-injected (NSC) and vehicle-injected (Veh) transgenic mice using ELISA kits (n = 4 per group). n and o Relative levels of BACE1
(NSC, n = 6; Veh, n = 5; n) and APP CTF-β/CTF-α (NSC, n = 4; Veh, n = 3; o) using western blot analyses in brains of hNSC-injected (NSC) and vehicle-
injected (Veh) transgenic mice. p APPsw-expressing SK-N-MC cells treated with hNSC-derived (NSC) and fibroblast-derived (Fib) CM (n = 3 per group,
where n is the number of experiments). Western blot image analysis of Aβ in the culture media of these cells, and BACE1, APP CTF-β/CTF-α, and
phosphorylated Akt and GSK3β in cells of both groups. The number of mice (n) in (b) and (l-o) is indicated. All data represent mean ± SEM. Error
bars indicate ± SEM. *p < 0.05
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Fig. 5 hNSC transplantation suppresses astrogliosis and microgliosis in the NSE/APPsw transgenic mouse brain. a–c Representative images of
GFAP+ astrogliosis in the hippocampus of vehicle-injected wild-type mice (WT-Veh; a), and of vehicle-injected (APP-Veh; b) and hNSC-injected
(APP-NSC; c) transgenic mice, at 7 weeks post-transplantation. Scale bar, 100 μm (c). d–f Representative images of Iba1+ microgliosis in the brains
of vehicle-injected wild-type mice (d), and of vehicle-injected (e) and hNSC-injected (f) transgenic mice, at 7 weeks post-transplantation. Scale
bar, 100 μm (f). Ga–Ib The hNSC transplantation substantially decreases the numbers of Iba1+ cells in the cortex (Gb) and hippocampus (Hb and
Ib) of transgenic mice compared with those in their vehicle-injected cohorts (Ga, Ha, and Ia). Scale bar, 100 μm (Ib). gcl, granular cell layer in the
dentate gyrus of the hippocampus. Ja–Kb The numbers of F4/80+ (Ja and Jb) and CD11b+ microglia (Ka and Kb) appear to decrease in the hippocampus
of hNSC-injected transgenic mice compared with those in their vehicle-injected cohorts. Scale bar, 50 μm (Jb and Kb). l Relative levels
of the optical density of GFAP immunoreactivity in the hippocampus of hNSC-injected (NSC, n = 3) and vehicle-injected (Veh, n = 3) transgenic mice.
m Relative levels of Iba1 immunoreactivity, quantified as a percentage of the area occupied using ImageJ, in the cortex (CTX) and hippocampus (HIPP)
of hNSC- and vehicle-injected transgenic mice (n = 3 per group). The number of mice (n) in L and M is indicated. All data represent mean ± SEM. Error
bars indicate ± SEM. *p < 0.05
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Human NSC transplantation enhances synaptic density
and prevents cell death
We analyzed synaptophysin (SVP) and postsynaptic
density protein 95 (PSD95) immunoreactivity and levels
to examine synaptic changes in hNSC- or vehicle-
injected NSE/APPsw transgenic mice. A significant
increase of synaptic density (p < 0.05 in both SVP and
PSD95) and levels (p < 0.05 in both SVP and PSD95)
were found between hNSC- and vehicle-injected mouse
brains (Fig. 7a–l), suggesting that hNSC transplantation
attenuated the synaptotoxic properties of Aβ and pro-
moted synaptic plasticity.
We performed a terminal deoxynucleotidyl transferase
dUTP nick-end labeling (TUNEL) assay and estimated
expression of active caspase-3 to investigate whether
hNSC transplantation prevents cell death in transgenic
mice. A substantial decrease in the number of TUNEL+
cells (85.9 ± 12.4 versus 135.7 ± 8.0, p < 0.05) and the
level of active caspase-3 (p < 0.05) were found in the
brains of hNSC-injected mice compared with that in
their vehicle-injected cohorts (Fig. 7m–p), demonstrat-
ing that hNSC transplantation protected host brain cells
against the cytotoxic environment of transgenic mouse.
Discussion
Because AD affects multiple neural systems and broad
regions of the brain, we performed intracerebroventricu-
lar transplantation of hNSCs in 13-month-old NSE/
APPsw transgenic mice to perpetuate widespread donor
cell engraftment, minimize transplantation-associated
tissue damage, and leverage endogenous mediators that
could elicit migration of implanted cells toward various
lesions. We observed that transplanted cells extensively
migrated and engrafted into various brain areas except
the hippocampus and remained mostly immature al-
though these cells were reliably multipotent, as previ-
ously described [12, 38]. Many studies reported that
implanted hNSCs predominantly differentiated into
astrocytes in various neurological disease models.
However, several other studies also observed differen-
tiation failure of engrafted hNSCs following trans-
plantation [15, 20, 22, 39, 40]. The difference in
differentiation patterns may be caused by the source
of the human cells, culturing techniques, and cell prepar-
ation, as well as potential differences between injury
models. In fact, engrafted hNSCs into disease models may
respond to both cell-intrinsic programming and local
environmental factors provided by multiple cellular and
acellular components. Thus, better understanding of a
broad spectrum of signals that occur in the AD-specific
pathologic conditions will be required to gain more
insights into the differentiation pattern of grafted cells.
These findings suggest that the beneficial effects of hNSC
grafting in this AD mouse model are not via cell replace-
ment; consequently, neuronal replacement by grafted cells
is unlikely.
In this study, the safety and feasibility of hNSC trans-
plantation were supported. There was no adverse finding
over 2–3 months after hNSC implantation into the brain
of NSE/APPsw transgenic mice. The transplantation
Fig. 6 hNSCs reduce the expression of pro-inflammatory mediators.
a Comparison of the expression of Il1b, Il6, Tnfa, and iNOS mRNA
levels in the brains of hNSC-injected (NSC, n = 7) and vehicle-
injected (Veh, n = 6) NSE/APPsw transgenic mice. b and d The
expression of Il1b, Il6, and Tnfa in LPS-stimulated BV2 microglial cells
co-cultured with hNSCs (BV2 + NSC) compared with that in single
cultures of LPS-stimulated BV2 cells (BV2) on Transwell permeable
supports (n = 3 per group; b). The hNSCs co-cultured with BV2 cells
(NSC + BV2) express TGFB1, IL4, and IL13 (d). c and e In mixed cultures,
the change of Il1b, Il6, Tnfa, and iNOS expression in LPS-stimulated
BV2 cells (BV2 + NSC) co-cultured with hNSCs compared with that in
single cultures of LPS-stimulated BV2 cells (BV2; n = 3 per group; c).
The hNSCs co-cultured with BV2 cells (NSC + BV2) express TGFB1,
IL4, IL13, CX3CL1, CD47, and CD200 (e). f The relative expression
of mRNA for Il1b, Il6, Tnfa, and iNOS in Tgfbr2-, Sirpa-, and Cd200r1-
knockdown BV2 cells co-cultured with hNSCs compared with that in
non-functioning negative siRNA (siNega)-transfected BV2 cells in mixed
co-culture in the presence of LPS (n = 3 per group). The number of
mice (n) in A is indicated. The number of experiments (n) in (b, c), and
(f) is indicated. All data represent mean ± SEM. Error bars indicate ±
SEM. *p < 0.05, **p < 0.01
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Fig. 7 hNSC transplantation increases synaptic density and decreases apoptosis in the NSE/APPsw transgenic mouse brain. a-h Photomicrographs
of SVP and PSD95 immunostaining (green and red puncta, respectively) in the posterior parietal cortex (a-d) and striatum radiatum of
the hippocampal CA1 region (e-f) in vehicle-injected (Veh; a, c, e, and g) and hNSC-injected (NSC; b, d, f, and h) transgenic mice at 7 weeks post-
transplantation. Scale bar, 25 μm (h). i and j Results of image analyses using confocal microscopy for synaptic density (SVP and PSD95) in the cortex
(CTX) and hippocampus (HIPP) comparing hNSC- and vehicle-injected transgenic mice (n = 4 per group; I, n = 3 per group; j). k and l Western blot
analysis of SVP (k) and PSD95 (l) in both groups (n = 3 per group). m and n Representative images of TUNEL+ cells in the posterior parietal cortex of
vehicle-injected (m) and hNSC- injected (n) transgenic mice at 7 weeks post-transplantation. Scale bar, 100 μm (h). o Quantification of the number of
TUNEL+ cells of the posterior parietal cortex in both groups (n = 3 per group). p The relative level of active caspase-3 in the whole brains of hNSC- and
vehicle-injected mice on western blot analysis (n = 4 per group). The number of mice (n) in (i-l, o, and p) is indicated. All data represent mean ± SEM.
Error bars indicate ± SEM. *p < 0.05
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procedure did not result in any harmful side effects;
infection, hemorrhage, tumor, atypical locomotion, spon-
taneous motor alterations, aberrant motor coordination,
or any behavioral abnormalities. Regarding mortality fol-
lowing transplantation, all mice groups in this study
showed similar death rate (APP-Veh, n = 3/43; WT-Veh,
n = 1/41; APP-NSC, n = 2/47; [n = number of mice dead/
total mice per group]).
We also demonstrated that hNSC transplantation
affected tau phosphorylation, Aβ production, neuroin-
flammation, synaptic density, and cell survival in the
transgenic mouse brain and identified those molecular
mechanisms likely involved in improving spatial memory
in these mice. It is reasonable to surmise that grafted cells
exert their therapeutic potency by modifying the dele-
terious milieu that contributes to AD pathologies
through influencing areas remote from the original
cell-injection site, either by migration or release of
diffusible factors. NSCs reportedly express not only a
wide range of trophic factors that restrain tau phos-
phorylation, Aβ production, and cell death but also
immunomodulatory factors [34, 41–48]. Therefore,
grafted hNSCs would be expected to express these
factors and interact with host cells via multiple mech-
anisms, resulting in the functional recovery of cogni-
tive deficits in NSE/APPsw transgenic mice.
NSE/APPsw transgenic mice undergo a marked increase
of tau phosphorylation, consistent with other AD mouse
models engineered with human mutant APP [26, 49]. The
hNSCs generated not only neurotrophins but also other
trophic factors, including VEGF, FGF2, and GDNF, that
activate Akt. Furthermore, hNSC transplantation in-
creased the levels of neurotrophins in the transgenic
mouse brain. Therefore, trophic factors augmented by
hNSC transplantation prevent tau phosphorylation via
Akt/GSK3β signaling because Akt activation inhibits tau
phosphorylation through GSK3β inactivation [50, 51].
However, NSC transplantation does not consistently inter-
fere with tau phosphorylation in other mouse models gen-
erated with human mutant tau, which ubiquitously
enhance tau phosphorylation and develop neurofibril-
lary tangles [21, 52]. Although the differences among
these studies are not fully understood, another study
[53] and ours demonstrated that NSC transplantation
perturbs tau phosphorylation induced by elevated Aβ.
Alternatively, the small decrease in Aβ levels observed
in the present study may have affected levels of phos-
phorylated tau because Aβ directly precedes aberrant
tau phosphorylation [54–56].
Accumulating evidence suggests that soluble Aβ oligo-
mers or intracellular Aβ may have a deteriorative effect
on cognitive function in AD mouse models [32, 33, 57].
In the present study, NSE/APPsw transgenic mice dis-
played intracellular Aβ deposits rather than excessive Aβ
plaques. Moreover, the production of Aβ is reduced by
pharmacological or genetic inhibition of GSK3β and
promoted by NGF and BDNF deprivation [46, 58–60].
Thus, trophic factors secreted from hNSCs would have
helped to reduce soluble Aβ in the transgenic mouse
brain and APPsw-expressing SK-N-MC cells due to
down-regulated Aβ production via Akt/GSK3β signaling.
We also found that the level of BACE1 was altered in
the brains of hNSC-grafted transgenic mice and in
hNSC-derived CM-treated APPsw-expressing cells.
These results are similar to other studies reporting that
BACE1 expression is decreased after activation of the
phosphatidylinositol 3-kinase/Akt and mitogen-activated
protein kinase/extracellular signal-regulated protein kin-
ase pathways, or inactivation of GSK3β [34, 35]. Add-
itionally, hNSCs do not affect the levels of Mme and Ide
in brains of NSE/APPsw transgenic mice following
transplantation, and do not effectively degrade soluble
Aβ42 peptides in vitro. Therefore, the decrease of sol-
uble intracellular Aβ in hNSC-transplanted transgenic
mice is attributable to the attenuated APP processing via
the Akt/GSK3β signaling-mediated reduction of BACE1
expression, not to the increased Aβ clearance. While the
exact nature of Aβ formation and tau phosphorylation
remains elusive, our findings strongly suggest that hNSC
transplantation mitigates aberrant tau phosphorylation
and intracellular Aβ accumulation through trophic
factor-dependent GSK3β inactivation in NSE/APPsw
transgenic mice.
Recently, some studies describe that trophic factors,
especially BDNF directly control tau phosphorylation
and Aβ production [46, 51]. Thus, to determine whether
BDNF secreted from hNSCs is directly involved in tau
phosphorylation and BACE1 expression in this study, we
tested brain slices from NSE/APPsw transgenic mice
with BDNF-depleted CM using immunoprecipitation.
The treatment of hNSC-derived CM significantly in-
duced the reduction of phosphorylated tau and BACE1
expression in brain slices compared with controls,
whereas BDNF-depleted CM revealed no significant
change in the level of tau phosphorylation and BACE1
(the Additional file 6: Figure S6). Thus, hNSC-secreted
BDNF is directly involved in regulating BACE1 expres-
sion as well as tau phosphorylation. However, besides
mechanistic studies using brain slices, further studies are
needed to ascertain that BDNF is dominantly involved in
tau phosphorylation and BACE1 expression by trans-
planting BDNF- as well as other factor-knockout hNSCs.
In the present study, astrogliosis and microgliosis
were enhance along with elevated expression of pro-
inflammatory mediators in NSE/APPsw transgenic
mice, consistent with observations in individuals with
AD and other mouse models of AD [3, 36]. Previous
reports indicate that neuroinflammation induced by
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chronically activated microglia in AD mouse models
exacerbates neurodegeneration, even though microglia
initially phagocytose Aβ [3]. NSC transplantation
markedly attenuates microgliosis and modulates im-
mune responses through interactions of grafted NSCs
with T cells, microglia, or dendritic cells in various neuro-
logical disease models [40, 42, 61–63]. In the present study,
hNSC transplantation reduced astrogliosis, microgliosis
and the expression of pro-inflammatory mediators in trans-
genic mice. Furthermore, hNSCs co-cultured with LPS-
stimulated microglial cells expressed anti-inflammatory
factors. We demonstrated in particular that TGF-β1,
CD200, and CD47 generated from hNSCs were directly
implicated in the expression of the pro-inflammatory medi-
ators in microglia. TGF-β1, an anti-inflammatory cytokine,
protects the brain against microglia-mediated neurotoxicity
and enhances microglial function for Aβ clearance [64, 65].
CD200 and CD47 constitutively maintain microglia in a
resting state and impede their pro-inflammatory activity
[66]. Therefore, our results suggest that hNSCs exert neu-
roinflammatory attenuation in transgenic mice by inducing
microglial deactivation. Alternatively, decreased expression
of IL-1β in hNSC-transplanted transgenic mouse brains
may reverse tau phosphorylation, as it was reported that
the release of IL-1β from microglia stimulates tau phos-
phorylation [67]. Moreover, the attenuation of neuroinflam-
mation may be associated with the reduction of BACE1
because anti-inflammatory drugs decrease BACE1 expres-
sion, leading to reduced Aβ levels [68, 69].
Through the regenerative and protective properties of
NSCs, NSC grafting increases synaptic plasticity and de-
creases apoptotic cell death via trophic supplies [15, 19,
21, 52, 70]. Similarly, our results suggest that hNSC
transplantation reinforces synaptic density and prevents
cell loss in NSE/APPsw transgenic mice.
Conclusions
This study demonstrated that human fetal brain-derived
NSCs showed extensive migration, robust engraftment,
long-term survival, differentiation into three CNS neural
cell types, albeit that most cells remained in an immature
state following transplantation. hNSC grafting not only
facilitate synaptic plasticity and anti-apoptotic function via
trophic supplies, but also decrease tau-phosphorylation
via Trk-dependent Akt/GSK3β signaling, Aβ production
via Akt/GSK3β-mediated reduced BACE1 expression, and
neuroinflammation through deactivation of microglia
mediated by cell-to-cell contact and secreted anti-
inflammatory factors, resulting in improved spatial mem-
ory in NSE/APPsw transgenic mice. Furthermore, the
safety and feasibility of hNSC transplantation are sup-
ported. There was no adverse finding after hNSC implant-
ation into the brain of transgenic mice. Thus, hNSCs are a
highly safe and effective therapeutic strategy for
treating AD by modulating complex brain systems
using multiple mechanisms. However, the cognitive
recovery following hNSC grafting was not maintained
over the long-term; thus, the long-term benefit of
hNSC transplantation remains unclear. With further
advances in understanding the pathology and discov-
ering novel therapeutic targets, hNSCs genetically or
non-genetically modified to release disease-modifying
proteins could be used as a versatile tool, adding to




NSE/APPsw transgenic mice were bred with background-
matched C57BL/6 mice. Heterozygous transgenic mice
and wild-type mice from the same litters were divided
based on genotyping at 3–4 weeks of age [26] and used at
13 months of age under a protocol approved by the Insti-
tutional Animal Care and Use Committee at Yonsei
University College of Medicine in Seoul, Korea. Mice were
housed in groups of 4–5 under a 12 h light/dark cycle at
22 °C, fed ad libitum, and maintained in a facility accre-
dited by the Association for the Assessment and Accredit-
ation of Laboratory Animal Care International.
Human NSC culture
Human fetal brain tissue from a cadaver at 13 weeks of
gestation was obtained with full parental consent and the
approval of the Research Ethics Committee of Yonsei
University College of Medicine (Permit Number: 4-2003-
0078). The hNSCs isolated from the telencephalon were
grown as neurospheres in serum-free culture medium
(DMEM/F12; Gibco, Grand Island, NY), N2 formulation
(Gibco), and 8 μg/ml of heparin (Sigma, St. Louis, MO)
supplemented with 20 ng/ml of FGF-2 (R&D Systems,
Minneapolis, MN) and 10 ng/ml leukemia inhibitory
factor (Sigma) [12]. hNSCs were maintained by passage
through dissociation of bulk neurospheres and cryopre-
served at each passage in a Good Manufacturing Practice
facility. As previously described [38], lenti-GFP particles
were prepared, and some hNSCs were transduced with a
multiplicity of infection of 1 and cultured.
Animal surgery and transplantation
At the time of grafting, hNSCs labeled with BrdU
(Sigma) for 5 days were dissociated with 0.05 % trypsin-
EDTA (Gibco) and washed three times with H-H buffer
(pH 7.4; Gibco). The entire cell pellet was then resus-
pended in H-H buffer at a density of 1 × 105 cells/μl.
Additionally, lenti-GFP-transduced hNSCs were pre-
pared in parallel. Mice were anesthetized with a mixture
of ketamine (50 mg/kg) and xylazine (Rompun, 10 mg/
kg), and then injected with 5 μl of vehicle or an hNSC
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suspension bilaterally into lateral ventricles (LVs; 0.1 mm
caudal, 0.9 mm bilateral to bregma, and 2.0 mm ventral
from the dura mater) of the brain at a flow rate of 1 μl/
min using a Hamilton syringe on an infusion pump (KD
Scientific, Holliston, MA). After the injection, the needle
was kept in place for 5 min before it was slowly with-
drawn. All mice received daily injections of cyclosporine
A (10 mg/kg, intraperitoneally) from the day before
transplantation to the end of the experiment.
Behavioral analysis
The open field test was conducted for 30 min or 22 h
using an infrared beam break detection system (Med
Associates, St. Albans, VT) to record the numbers of
ambulatory and stereotyped activities for 5 min or 2 h
per session. The accelerating rotarod task measured the
latencies to fall off the rod (LSi Letica; Panlab, Barce-
lona, Spain) that was accelerated gradually from 4 to
40 rpm for the 5 min test period. The Morris water
maze test was conducted with automated video tracking
software (Smart; Panlab). A mouse was placed next to
and facing the wall in four individual directions with a
hidden escape platform using an intertrial interval of
15 min for 6 consecutive days. After the acquisition
phase, the probe trial was conducted without the plat-
form present on day 7. The mouse was allowed to swim
for 1 min. Additional details are described in the
Additional file 7.
Immunohistochemistry
At 7 weeks post-transplantation, the brains were fixed
and coronally sliced into 20 μm sections as described
[38]. The sections on the slide were blocked with 10 %
normal donkey serum (Jackson ImmunoResearch, West
Grove, PA), 3 % bovine serum albumin, and 0.3 % Tri-
ton X-100 in PBS. BrdU staining required treatment
with 2 N HCl for 30 min at 37 °C prior to blocking.
The sections were incubated with antibodies as de-
scribed in the Additional file 8: Table S1 and visualized
with fluorescein- or Texas Red-conjugated antibodies
(Vector, Burlingame, CA). Alternatively, after treatment
with 0.3 % H2O2 in methanol, immunolabeling for Aβ
plaques required treatment with 70 % formic acid for
15 min [71]. The sections were incubated with mouse
anti-Aβ1-16 (6E10, 1:200; Covance, Dedham, MA),
rabbit anti-Aβ42 (1:100; Invitrogen, Carlsbad, CA) or
mouse anti-PHF-tau (AT180, 1:200; Thermo Scientific,
Rockford, IL) antibodies, followed by biotinylated anti-
bodies (Jackson ImmunoResearch), and were visualized
using the Vectastain Elite ABC kit according to the
manufacturer’s instructions. Other sections for the
TUNEL assay were subjected to an In Situ Cell Detec-
tion Kit (Roche, Mannheim, Germany) following the
manufacturer’s procedures. Immunolabeled specimens
were observed with an Olympus BX51 microscope and
a Zeiss LSM 700 confocal microscope and analyzed
with ImageJ version 1.46r software (National Institutes
of Health). Additional details were provided in the
Additional file 7.
Western blot and ELISA
Mouse brains were homogenized in Tissue Protein Ex-
traction Reagent (Thermo Scientific) containing protease
and phosphatase inhibitors (Sigma) at 7 weeks post-
transplantation. The homogenates were briefly sonicated
and then centrifuged for 1 h at 1 × 105 g. The pellet was
subsequently re-homogenized in 70 % formic acid and
centrifuged for 1 h at 1 × 105 g. The first and second su-
pernatants were prepared as the detergent-soluble and
insoluble fractions, respectively. Samples were electro-
phoresed in 10 % Tris-glycine gels, 4 − 15 % Mini-
protean TGX precast gels (Bio-Rad, Hercules, CA), or
16.5 % Tris-tricine gels, and transferred to nitrocellulose
membranes. After being blocked with 5 % skim milk or
bovine serum albumin in TBS containing 0.1 or 0.05 %
Tween 20, the membranes were incubated with anti-
bodies as described in the Additional file 8: Table S1.
Next, the membranes were incubated with peroxidase-
conjugated antibodies (Jackson ImmunoResearch), treated
with SuperSignal West Pico or Dura chemiluminescent
substrate (Thermo Scientific), and observed with an LAS-
4000 mini (GE Healthcare, Wausaukee, WI). Protein bands
were analyzed as the signal intensity ratio between target
protein and β-actin using Multi Gauge version 3 software
(Fujifilm, Tokyo, Japan). Aβ40 and Aβ42 levels were mea-
sured with ELISAs using the human Aβ1 − 40 or Aβ1 − 42
assay kit (Immuno-Biological Laboratories, Minneapolis,
MN) in accordance with the manufacturer’s instructions.
Quantitative PCR
The RNA was isolated from hNSCs, BV2 murine micro-
glial cells, or mouse brains at 7 weeks post-transplantation
using TRI Reagent solution (Molecular Research Center,
Cincinnati, OH) and reverse-transcribed into cDNA using
SuperScript III Reverse Transcriptase (Invitrogen). The
quantitative (q)PCR was performed in 384-well plates with
LightCycler 480 SYBR Green I Master mix (Roche) on a
LightCycler 480 System (Roche) as follows: 95 °C for
5 min and 45 cycles of 95 °C for 10 s, 60 °C for 20 s, and
72 °C for 15 s, followed by a melting curve program. The
forward and reverse primers (Additional file 9: Table S2)
were designed using PrimerBank and RTPrimerDB data-
bases (http://pga.mgh.harvard.edu/primerbank/index.html
and http://www.rtprimerdb.org). The relative gene
expression was analyzed using advanced relative quan-
tification based on the E-method provided by
Roche Applied Science. Expression levels were
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normalized against Gapdh or 18S rRNA with a PCR
efficiency correction.
Treatment of conditioned media
The CM from hNSCs and fibroblasts were concentrated
10-fold using Amicon Ultra-0.5 centrifugal filter devices
(Millipore, Milford, MA), according to the manufac-
turer’s manual. More details were described in the Sup-
porting Information. Differentiated PC12 cells (4 × 105)
[30] on six-well plastes were treated with 2 μM soluble
Aβ42 (Invitrogen) in the presence of concentrated CM
in RPMI 1640 medium (Gibco) for 24 h. Soluble Aβ42
was prepared as previously described [72]. APPsw-ex-
pressing SK-N-MC cells (2 × 105) [38] were seeded on
six-well plates in growth medium, and then the
medium was completely exchanged for fresh DMEM
the following day in the presence of concentrated
CM. The cultured media were immunoprecipitated
with 4 μg of anti-6E10 after 24 h, using 20 μl of
Dynabead ProteinG (Invitrogen) according to the
manufacturer’s protocol to estimate Aβ content. The
cells were lysed in RIPA buffer (Thermo Scientific)
with Halt Protease and Phosphatase Inhibitor Cocktail
(Thermo Scientific) for western blot.
Co-culture of hNSCs and BV2 cells
The hNSCs (1.2 × 106) were differentiated on PLL-coated
six-well plates (lower chamber) for 3 days and were then
co-cultured with BV2 microglial cells (1.2 × 106) on the
0.4 μm porous inserts (upper chamber) of Transwell per-
meable supports (Corning, Corning, NY) in serum-free
culture medium with added LPS for 24 h. Addition-
ally, hNSCs (2 × 106) differentiated on PLL-coated
6 cm dishes for 5 days were directly co-cultured with
BV2 cells (2 × 106) in the presence of LPS. Mixed cul-
tures of hNSCs and BV2 cells were separated using
fluorescence-activated cell sorting (FACS; FACSAria
II; sort nozzle, 100 μm, and sheath pressure, 20 psi)
after 24 h. The hNSCs and BV2 cells were dissolved
in TRI reagent.
Transfection of small interfering RNA
The BV2 microglial cells were transfected with 10 μM
Tgfbr2 small interfering RNA (siRNA) (sense, 5′ CAGAA
GAUGGCUCGCUGAAdTdT 3′; antisense, 5′ UUCAGC
GAGCCAUCUUCUGdTdT 3′), Sirpa siRNA (sense, 5′
CUCUACCCAACUUGAGCUUdTdT 3′; antisense, 5′ A
AGCUCAAGUUGGGUAGAGdTdT 3′), Cd200r1 siRNA
(sense, 5′ CUCUAUGAUACUGUGACUAdTdT 3′; anti-
sense, 5′ UAGUCACAGUAUCAUAGAGdTdT 3′), or
non-functioning negative-control siRNA (sense, 5′ CCU
ACGCCACCAAUUUCGUdTdT 3′; antisense, 5′ ACGA
AAUUGGUGGCGUAGGdTdT 3′) using Lipofectamine
RNAiMAX reagent (Invitrogen) according to the
manufacturer’s protocols. All siRNAs were purchased
from Bioneer (Daejeon, Korea). After 3 h of siRNA lipo-
fection in these co-cultures, LPS was added to the cul-
tures. The BV2 cells were separated from the mixed
cultures after a 24 h LPS treatment and used for qPCR.
Statistical analysis
Statistical analyses were conducted using SPSS version
20 (IBM Corp., Armonk, NY) software. Behavioral values
were subjected to repeated-measures ANOVA or one-
way ANOVA, followed by post hoc Scheffé’s tests. Differ-
ences between two groups were assessed using the
Mann–Whitney U-test as a non-parametric analysis.
Data are presented as means ± standard error of the
means (SEM), error bars indicate ± SEM, and p-values
<0.05 were considered statistically significant.
Additional files
Additional file 1: Figure S1. GFP expression by lenti-GFP-transduced
hNSCs. Proliferating lenti-GFP-transduced hNSCs form neurospheres in
culture dishes (A) and express GFP (B). Flow cytometry analysis using FlowJo
(version 9.3.3) software showed that 94.5 % of all cells are GFP-positive (blue
line histogram in C). The red line histogram is the negative control. Scale
bar, 100 μm. (TIFF 310 kb)
Additional file 2: Figure S2. Histological analysis of transplanted hNSCs
into NSE/APPsw transgenic mice at 3 months post-grafts. (A–D) Some
grafted hNuC+ and human cytoplasmic marker SC121+ cells are found in
the subventricular zone (A and B), third ventricle (C), and hypothalamus
(D). Z-stack images are built and compiled to maximal intensity projections.
Scale bars, 50 μm (A-D). (E–G) Most grafted hNuC+ (red) cells expressed
hnestin (green; E) whereas some cells are co-localized with either TUJ1
(green; F) or GFAP (green; G). Scale bars, 25 μm (E-G). (H) A few of SC121+
(red) cells express Olig2. Scale bars, 25 μm. In E–H, confocal image stacks are
orthogonally presented as x–z (bottom) and y–z (right) planes indicated by
the vertical green and horizontal red lines, respectively. (TIFF 5979 kb)
Additional file 3: Figure S3. hNSCs express diverse trophic factors. (A)
In vitro proliferating and differentiated hNSCs expressed BDNF, NTF3, NTF4,
NGF, VEGF, FGF2, and GDNF. (B) Western blotting analysis showed that
hNSCs secreted higher levels of BDNF, NTF3, NTF4, NGF, and VEGF into
the culture medium than human foreskin fibroblasts secrete. (TIFF 127 kb)
Additional file 4: Figure S4. The expression of Aβ-degrading enzymes
in both in vivo and in vitro. (A) Transplantation of hNSCs (NSC, n = 7) did
not significantly alter the levels of Mme and Ide expression in NSE/APPsw
transgenic mice compared with vehicle injection (Veh, n = 6). (B) In vitro
expression of Aβ-degrading enzymes in hNSCs. hNSCs under proliferation
and differentiation conditions expressed IDE, MME, ECE1 (endothelin
converting enzyme 1), ECE2 (endothelin converting enzyme 2), MMP2
(matrix metalloproteinase 2), PLAT (plasminogen activator, tissue),
PLAU (plasminogen activator, urokinase), ACE (angiotensin 1 converting
enzyme), and CTSB (cathepsin B). On western blot, there were no differences
in the levels of Aβ42 in the media containing 1 μM soluble Aβ42 peptides
between wells with and without incubation with hNSCs for 2 days. The
number of mice (n) in A is indicated. All data represent mean ± SEM.
Error bars indicate ± SEM. (TIFF 3170 kb)
Additional file 5: Figure S5. The separation of mixed co-cultured
hNSCs and BV2 microglial cells. (A) Representative images of human NSCs
and lipopolysaccharide (LPS)-activated BV2 cells separated by flow cytometry
from a mixed co-culture. Human NSCs and LPS-activated BV2 cells were
sorted based on different combinations of forward scatter-A (FSC-A, cell size)
and side scatter-A (SSC-A, granularity). The percentage of hNSCs and BV2 cells
is 18.6 and 71.6 %, respectively, in the co-culture of hNSCs (FSC-Alo/SSC-Alo)
and LPS-activated BV2 cells (FSC-Ahi/SSC-Ahi). The sorted hNSCs and
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LPS-activated BV2 cells are rarely included with other cells (<3 %).
(B) The siRNA-lipofected BV2 cells decrease target gene expression (>50 %;
n = 3 per group). The number of experiments (n) is indicated. All data
represent mean ± SEM. All error bars indicate SEM. Mann–Whitney U-test,
*p < 0.05. (TIFF 527 kb)
Additional file 6: Figure S6. NSE/APPsw transgenic mouse-derived
brain slices treated with BDNF-depleted CM. (A) Western blot showed
that hNSCs secreted high level of BDNF into the cultured medium
(lane 1; CM), and anti-BDNF antibody-mediated immunoprecipitation
effectively removed BDNF in CM (lane 2; BDNF-depleted CM). Another
SDS-PAGE gel was in parallel performed with silver staining to verify even
loading. (B) Brain slices treated with DMEM (Ctr), CM, BDNF-depleted CM.
Western blot analysis of phosphorylated tau (AT180) and BACE1
(n = 3 per group, where n is the number of experiments). All data
represent mean ± SEM. Error bars indicate ± SEM. Mann–Whitney
U-test, *p < 0.05. (TIFF 2110 kb)
Additional file 7: Additional details of Methods. (DOCX 33 kb)
Additional file 8: Table S1. List of primary antibodies used in
immunohistochemistry (IHC) and western blot (WB). (DOCX 28 kb)
Additional file 9: Table S2. Sequences of primers used for reverse
transcription (RT) and quantitative (q) PCR. (DOCX 25 kb)
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